Prophylactic treatment of retinal breaks reduces RD risk

Article

Prophylactic treatment of retinal breaks during vitrectomy appears to reduce the risk of postoperative retinal detachment (RD).

Prophylactic treatment of retinal breaks during vitrectomy appears to reduce the risk of postoperative retinal detachment (RD), states a paper in Retina.

The retrospective non-comparative interventional case series, led by Dr H.S. Tan, Department of Ophthalmology, Academic Medical Centre, University of Amsterdam, Amsterdam, The Netherlands, reviewed the medical records of 89 consecutive cases of 89 patients over a period of four years. The main outcome measures included incidence of breaks, visual acuity outcome and occurrence of postoperative complications.

The findings demonstrated that the visual acuity at the last follow-up visit was ≥0.5 in 70% of patients. Retinal breaks were found in 29% of patients, but induction of a posterior vitreous detachment, the use of a fragmatome or delay between cataract surgery and vitrectomy did not affect retinal break incidence.

Only 2% of cases presented with postoperative RD, one case had intraoperative choroidal haemorrhage, two cases had postoperative macular pucker, one had postoperative macular oedema and glaucoma was recorded in two cases.

A high number of retinal breaks were observed during vitrectomy for retained lens fragments. Prophylactic treatment of retinal breaks appears to reduce the risk of postoperative RD.

Please click here to read the abstract.

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.